The altered PD-L1 expression after neoadjuvant chemotherapy in patients with squamous NSCLC (36) should be also taken into account when treating patients with NSCLC with PD-L1 ≤49%, because underestimation of the expected outcome of ICI monotherapy in this population would lead to avoidance of the ICI treatment. The gene discussed is CD274; the disease is non-small cell lung carcinoma.